Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7513)
All Articles published online
|
Publishing Process of This Article
|
Jul 28, 2022 (publication date) through Mar 8, 2026
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| Nishimoto A. Effective combinations of anti-cancer and targeted drugs for pancreatic cancer treatment. World J Gastroenterol 2022; 28(28): 3637-3643 [PMID: 36161054 DOI: 10.3748/wjg.v28.i28.3637] |
|
|
|
| ©2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA | |
| For: | Nishimoto A. Effective combinations of anti-cancer and targeted drugs for pancreatic cancer treatment. World J Gastroenterol 2022; 28(28): 3637-3643 [PMID: 36161054 DOI: 10.3748/wjg.v28.i28.3637] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v28/i28/3637.htm |
| Number | Citing Articles |
| 1 |
Tianqi Xu, Alexey Schulga, Elena Konovalova, Sara S. Rinne, Hongchao Zhang, Olga Vorontsova, Anna Orlova, Sergey M. Deyev, Vladimir Tolmachev, Anzhelika Vorobyeva. Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin–Toxin Fusion in a Pancreatic Cancer Xenograft Model. International Journal of Molecular Sciences 2023; 24(3): 2838 doi: 10.3390/ijms24032838
|
| 2 |
Jordan Powell, Alexa F. Viniotis, Chase Irwin, Gayle S. Jameson, Lana Caldwell, Erkut H. Borazanci. Retrospective analysis of capecitabine maintenance therapy in pancreatic ductal adenocarcinoma. Therapeutic Advances in Medical Oncology 2025; 17 doi: 10.1177/17588359251321894
|
| 3 |
Jiongjia Cheng, Ting Zhu, Shaoxian Liu, Jiayu Zhou, Xiaofeng Wang, Guangxiang Liu. Prediction of synergistic gemcitabine-based combination treatment through a novel tumor stemness biomarker NANOG in pancreatic cancer. RSC Medicinal Chemistry 2024; 15(11): 3853 doi: 10.1039/D4MD00165F
|
| 4 |
Jinghui Jin, Juan Nan, Yanpo Si, Xiaohui Chen, Haibo Wang, Xiaowei Wang, Jingwang Huang, Tao Guo. Exploring the therapeutic potential of rabdoternin E in lung cancer treatment: Targeting the ROS/p38 MAPK/JNK signaling pathway. Molecular Medicine Reports 2024; 30(5) doi: 10.3892/mmr.2024.13330
|
| 5 |
Ri Huang, Hong Du, Liang Cheng, Ning Zhao, Peizhuo Zhang, Fenghua Meng, Zhiyuan Zhong. Targeted Delivery of siRNA-Gemcitabine Oligonucleotide Chimeras for High-Efficacy Synergistic Treatment of Pancreatic Cancer. Chemistry of Materials 2024; 36(24): 11881 doi: 10.1021/acs.chemmater.4c02335
|
| 6 |
Julien Boudreault, Shima Rahimirad, Ni Wang, Gang Yan, Leslie Chaltel Lima, Sophie Poulet, Meiou Dai, Suhad Ali, Jean-Jacques Lebrun. Identification of HSPE1 as a new actionable cancer vulnerability leads to an innovative and effective combination therapy for pancreatic ductal adenocarcinoma. Molecular Cancer 2026; doi: 10.1186/s12943-026-02587-9
|
| 7 |
Ning Cheng, Li Wang, Yiping Liu, Bosheng Song, Changsong Ding. HANSynergy: Heterogeneous Graph Attention Network for Drug Synergy Prediction. Journal of Chemical Information and Modeling 2024; 64(10): 4334 doi: 10.1021/acs.jcim.4c00003
|
| 8 |
Tejinder Kaur, Debasis Nayak, Arnav Joshi, Junan Li, Amy Hite, Rajgopal Govindarajan. Loss of Regulator of G Protein Signaling 11 Promotes Protumorigenic Features in Pancreatic Cancer. Molecular Cancer Research 2026; 24(1): 34 doi: 10.1158/1541-7786.MCR-25-0144
|
| 9 |
Jay Natu, Ganji Purnachandra Nagaraju. Gemcitabine effects on tumor microenvironment of pancreatic ductal adenocarcinoma: Special focus on resistance mechanisms and metronomic therapies. Cancer Letters 2023; 573: 216382 doi: 10.1016/j.canlet.2023.216382
|
| 10 |
Priti Gupta, Charles F. Hodgman, Claudia Alvarez-Florez, Keri L. Schadler, Melissa M. Markofski, Daniel P. O’Connor, Emily C. LaVoy. Comparison of three exercise interventions with and without gemcitabine treatment on pancreatic tumor growth in mice: No impact on tumor infiltrating lymphocytes. Frontiers in Physiology 2022; 13 doi: 10.3389/fphys.2022.1039988
|
| 11 |
Jun-Hao Huang, Wei Guo, Zhe Liu. Discussion on gemcitabine combined with targeted drugs in the treatment of pancreatic cancer. World Journal of Gastroenterology 2023; 29(3): 579-581 doi: 10.3748/wjg.v29.i3.579
|
| 12 |
Ziying Zhou, Yi Nan, Xiangyang Li, Ping Ma, Yuhua Du, Guoqing Chen, Na Ning, Shicong Huang, Qian Gu, Weiqiang Li, Ling Yuan. Hawthorn with “homology of medicine and food”: a review of anticancer effects and mechanisms. Frontiers in Pharmacology 2024; 15 doi: 10.3389/fphar.2024.1384189
|
| 13 |
Roshini Pradeep, Nooredeen Jamal Isbeih, Freya F. Abraham, Ehsan Noori, Zachary P. Yeung, Madappa N. Kundranda. KRAS Inhibition in Pancreatic Ductal Adenocarcinoma. Journal of Clinical Medicine 2026; 15(2): 873 doi: 10.3390/jcm15020873
|
| 14 |
Junliang Chen, Zhihao Liu, Zhiyuan Wu, Wenjun Li, Xiaodong Tan. Identification of a chemoresistance-related prognostic gene signature by comprehensive analysis and experimental validation in pancreatic cancer. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1132424
|
| 15 |
Yanfang Cao, Renwei Xing, Fan Yang, Yang Zhang, Xianfei Zhou. Establishment of a prognostic model for pancreatic cancer based on vesicle-mediated transport protein-related genes. Computer Methods in Biomechanics and Biomedical Engineering 2025; 28(15): 2312 doi: 10.1080/10255842.2024.2367739
|
| 16 |
Arian Ansardamavandi, Chelsea Dumesny, Sarah Ellis, Ching-Seng Ang, Mehrdad Nikfarjam, Hong He. Targeting PAK1 or PAK4 Uncovers Different Mechanisms of Vascular Reprogramming in Pancreatic Cancer. Cells 2025; 14(22): 1806 doi: 10.3390/cells14221806
|
| 17 |
Jae Hyeong Kim, Yuna Youn, Jin-Hyeok Hwang. <i>SLFN11</i> Deficiency-Induced Gemcitabine Resistance Is Overcome by Agents Targeting the DNA Damage Response in Pancreatic Cancer Cells. BIOCELL 2025; 49(4): 681 doi: 10.32604/biocell.2025.062144
|
| 18 |
Yugandhar Kothapalli, Tucker A. Lesperance, Ransom A. Jones, Chung K. Chu, Uma S. Singh. Chemical Space of Fluorinated Nucleosides/Nucleotides in Biomedical Research and Anticancer Drug Discovery. Chemistry 2025; 7(1): 7 doi: 10.3390/chemistry7010007
|
| 19 |
Jianxi Huang, Yu-Ting Chien, Qingxin Mu, Miqin Zhang. An Efficient Fabrication Approach for Multi-Cancer Responsive Chemoimmuno Co-Delivery Nanoparticles. Pharmaceutics 2024; 16(10): 1246 doi: 10.3390/pharmaceutics16101246
|